Exploring the Role of Sclerostin as a Biomarker of Cardiovascular Disease and Mortality: A Scoping Review
Metadatos
Mostrar el registro completo del ítemAutor
Sanabria de la Torre, Raquel; González Salvatierra, Sheila; García Fontana, Cristina; Andújar Vera, Francisco Luis; García Fontana, Beatriz; Muñoz Torres, Manuel Eduardo; Riquelme Gallego, BlancaEditorial
MDPI
Materia
Biomarkers Cardiovascular disease Cardiovascular mortality Cardiovascular risk Sclerostin
Fecha
2022-11-30Referencia bibliográfica
Sanabria-de la Torre, R... [et al.]. Exploring the Role of Sclerostin as a Biomarker of Cardiovascular Disease and Mortality: A Scoping Review. Int. J. Environ. Res. Public Health 2022, 19, 15981. [https://doi.org/10.3390/ijerph192315981]
Patrocinador
Instituto de Salud Carlos III European Commission PI18-00803 PI21/01069 PI18-01235 CD20/00022; European Commission; Junta de Andalucia PI-0268-2019 RH-0069-2021; Instituto de Salud Carlos III; University of Granada FI19/00118; European Commission 8110Resumen
Sclerostin is most recognized for its role in controlling bone formation; however, it is also
expressed in the heart, aorta, coronary, and peripheral arteries. Human studies have associated high
circulating sclerostin levels with the presence of different cardiovascular diseases (CVD), surrogate
CVD markers, and a high risk of cardiovascular events in some populations. However, this is still a
matter of scientific debate, as the results have been very heterogeneous among studies. In the present
review, the association between serum sclerostin levels and CVD and/or cardiovascular mortality
was analyzed. For this purpose, a scoping review was performed in which articles measuring serum
sclerostin levels and cardiovascular risk in patients were selected. Eleven articles answered the
research question; of these articles, 8/11 evaluated the association between sclerostin and CVD, of
which 4/8 found a positive association, 2/8 found a negative association, and 2/8 found no association
between variables. Five (5/11) of the articles included in the study evaluated cardiovascular
mortality, of which 3/5 found a positive association, 1/5 found a negative association, and 1/5
found no association between variables. In conclusion, we did not find sufficient results to be able to
demonstrate an association between elevated sclerostin levels and the development of CVD and/or
cardiovascular mortality in the general population due to heterogeneity in the results. However, there
seems to be a tendency to consider increased sclerostin levels as a risk factor for both the development
of cardiovascular events and cardiovascular mortality in specific populations. Further studies in this
field will help to solve some of the inconsistencies found during this scoping review and allow for the
future use of sclerostin measurement as a strategy in the prevention and diagnosis of CVD and/or
cardiovascular mortality.